Navigation Links
ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials
Date:8/27/2007

PARIS, August 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announced that its drug discovery collaboration with Allergan Inc. (NYSE: AGN), a global speciality pharmaceutical and medical device company, has reached a success milestone. As a result of the efforts of the Allergan and ExonHit research team, human clinical testing will be initiated on the first collaboration New Chemical Entity (NCE). This NCE (designated EHT/AGN001) has a novel mechanism of action and will enter a phase I study later this year.

The objectives of Allergan and ExonHit's strategic collaboration are to identify, develop and commercialise drugs targeted at the treatment of neurodegenerative diseases, pain and ophthalmology. The collaboration was initiated in 2003 and has been extended twice as a consequence of its good productivity.

"We are happy to see that this collaboration has lead to a clinical candidate in such a short period of time. This success is a result of the dedicated efforts and focus by the research teams from both companies," said Dr. Scott Whitcup, Executive Vice President, Research & Development of Allergan Inc.

"By industry standards, this collaboration's productivity is exceptional, delivering a clinical product in less than four years together with two other innovative pre-clinical projects," stated Bruno Tocque President of the Management Board of ExonHit. He added "I would like to express my gratitude to our scientists who have developed a drug discovery engine enabling this achievement".

Under the terms of the agreement, Allergan will assume responsibility for the ongoing clinical development and commercialisation of EHT/AGN001. Contingent upon
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... -- DuPont (NYSE: DD ) announced that at ... today in New York , DuPont ... strategy, progress and plans to accelerate growth in the ... the company,s leading position in high-value advanced materials is ... DuPont. Discussing the company,s Advanced Materials segments, ...
(Date:3/5/2015)... 05, 2015 LifeCell Dx and its ... to get an Advanced Semen Analysis before they do ... guessing are all risk factors for struggling couples.Too often, ... the source of the infertility. Infertility is fairly equally ... the simplest, least complicated and inexpensive analysis that ...
(Date:3/5/2015)... IDAHO (PRWEB) March 05, 2015 ... Ultralight Histology’s paraffin and stain additive. The improvement ... observe the binary features present in all daughter ... FFPE protocol, chromatin packaging was analyzed at 1000-1600x ... indicated that chromatin patterning in all daughter cells ...
(Date:3/5/2015)... Conn. , March 5, 2015  UBM ... , a leading online community to help ... of the newest information available regarding the use ... of kidney cancer. March is ... are very few effective adjuvant treatment options for ...
Breaking Biology Technology:DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3
... P&G,s Commitment to Sustainable Innovation., Accelerates LS9,s Entry into ... ... South San Francisco, CA (PRWEB) -- LS9, Inc., the ... Procter and Gamble (NYSE: PG), one of world,s largest consumer ...
... goBalto.com , ... San Francisco, CA ... partnering site for the pharmaceutical development and drug manufacturing industry, ... of India-based Investigator Sites and hospitals available on goBalto.com. , ...
... Reprints NRx for the Force.com AppExchange saves time for ... process from within Salesforce CRMSANTA MONICA, Calif., May 19 ... announced the availability of Reprints NRx for ... the Force.com platform, Reprints NRx for the AppExchange is ...
Cached Biology Technology:LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership 2goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites 2goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites 3Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... Jan. 13, 2015 Technology Showcase, Hall E -   ... solutions, today announced it will showcase its EyeLock ID technology ... the Department of Energy,s Oak Ridge National Laboratory ... . EyeLock,s iris identity authentication technology is being used to ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... are developing a cost-effective electronic monitoring system that will ... ecosystems by allowing users to track water-quality data from ... a National Science Foundation (NSF) grant. "Our goal ... environmental conditions in the Chesapeake Bay, the sounds of ...
... to help the government cut through red tape and roll ... This week, the university,s Durham Energy ... meet with the Department of Energy & Climate Change to ... on Wednesday November 3rd will also be attended by Ofgem ...
... Calif., Nov. 1, 2010 General Manifolds LLC, a ... that the United States Patent and Trademark Office has ... method for simulating functions within the cerebral cortex of ... a broad range of applications from artificial intelligence to ...
Cached Biology News:Researchers developing real-time electronic monitoring for coastal waters 2Durham Energy Institute to advise government on green technology 2General Manifolds LLC Announces Issuance of US Patent in Computational Neuroscience 2
...
... new Class II safety cabinets Heraeus HERAsafe KS ... user-orientated design. ,The new frameless slanted window ... area. The new front window design makes it ... large work aperture with a height of more ...
... launched a custom synthesis service for ... siRNA molecules are: Composed of ... bases overhang at the 3-terminus ... deprotected and ready-to-use. Simply order ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: